JavaScript is disabled in your browser. Please enable JavaScript to view this website.

HRAS

GeneName

HRAS

Summary

HRAS, also known as Ras or p21ras, is a small GTPase that plays a pivotal role in cellular signalling pathways, particularly in the regulation of cell growth and differentiation. It is primarily localised to the plasma membrane but can also be found in various cellular compartments including the cytoplasm, Golgi apparatus, and nucleus. HRAS functions by binding to GTP and GDP, acting as a molecular switch that transduces signals from cell surface receptors to downstream effectors, such as the MAPK cascade. This protein is involved in multiple biological processes, including adipose tissue development, chemotaxis, and the regulation of cell cycle and proliferation. Its activity is crucial for proper cellular responses to external stimuli and contributes to oncogenic processes when mutated.

Importance

HRAS is relevant to: - Cancer research, as mutations in HRAS are implicated in various malignancies, including bladder and thyroid cancers. - Understanding cell signalling mechanisms, particularly those related to growth factor receptors and oncogenic pathways. - Developmental biology, given its role in organ morphogenesis and tissue development. - Neurological studies, due to its involvement in neuronal signalling and synaptic plasticity.

Top Products

For researchers investigating HRAS, we highly recommend the top-selling recombinant antibody, Anti-Ras antibody [EP1125Y] (ab52939). This antibody has been validated for use in several applications, including Western blotting (WB), immunocytochemistry (ICC), immunoprecipitation (IP), and flow cytometry (FC), making it a versatile tool for your research needs. With 100 citations, it is well-regarded in the scientific community, reflecting its reliability and effectiveness in HRAS studies. The Human HRAS ELISA Kit (ab267797) is an excellent option for researchers looking to measure HRAS levels in their samples.

Abcam Product Citation Summary

The data indicates a strong focus on the role of HRAS in various cellular contexts, particularly in human and rat cell lines. The studies primarily utilise Western blotting to investigate HRAS's involvement in pathways such as Ras/Raf/MEK/ERK and VEGF-induced migration, as well as its implications in cell apoptosis and growth factor signalling. The use of immunofluorescence in some studies highlights the interest in visualising HRAS activity in different cellular environments.

Abcam Product Citation Table

Product Code
Species
Application
Study Context
PMID
ab16907
Human
IF
Effects of vitamin C on the EGFR/MAPK signaling pathway
27323830
ab16907
Human
WB
Ras/Raf/MEK/ERK pathway
31783811
ab32417
Human
WB
VEGF-induced migration
23548900
ab32417
Human
WB
Ras activation
27468687
ab52939
Human
WB
Cell apoptosis and growth factors
28341836
ab52939
Rat
WB
Ras-MAPK signaling
28374012
ab52939
Rat
WB
Oligomeric Aβ42 treatment
28374012
ab52939
Rat
WB, IHC-IF, ICC-IF
Oligomeric Aβ42 treatment
28374012
ab52939
Rat
WB
Aβ-mediated signaling
28374012
ab52939
Human
WB
MCF-7 cells treated with Tan IIA
29416003
ab52939
Human
WB
Brain samples from MCI and LAD patients
28374012
ab52939
Rat
WB
Ras-ERK signaling
28374012
ab52939
Rat
WB
Ras activation
28374012
ab52939
Human
WB
HEK293 cells
26612112
ab52939
Human
WB
Ras/Raf/MEK/ERK pathway
31443651
ab52939
Human
WB
Ras/Raf/MEK/ERK pathway
31443651

Function

Involved in the activation of Ras protein signal transduction (PubMed:22821884). Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:12740440, PubMed:14500341, PubMed:9020151).

Involvement in disease

Costello syndrome

CSTLO

A rare condition characterized by prenatally increased growth, postnatal growth deficiency, intellectual disability, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.

None

The disease is caused by variants affecting the gene represented in this entry.

Congenital myopathy with excess of muscle spindles

CMEMS

Variant of Costello syndrome.

None

The disease is caused by variants affecting the gene represented in this entry.

Thyroid cancer, non-medullary, 2

NMTC2

A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.

Bladder cancer

BLC

A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Schimmelpenning-Feuerstein-Mims syndrome

SFM

A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis.

None

The disease is caused by variants affecting the gene represented in this entry.

Post-translational modifications

Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.

S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.

The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur as an alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.

Acetylation at Lys-104 prevents interaction with guanine nucleotide exchange factors (GEFs).

Fatty-acylated at Lys-170.

Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at Lys-170 in a non-degradative manner, leading to inhibit Ras signaling by decreasing Ras association with membranes.

(Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin TcsL (PubMed:19744486, PubMed:8626575, PubMed:8626586, PubMed:9632667). Monoglucosylation completely prevents the recognition of the downstream effector, blocking the GTPases in their inactive form, leading to inhibit Ras signaling (PubMed:8626575, PubMed:8626586, PubMed:9632667).

Sequence Similarities

Belongs to the small GTPase superfamily. Ras family.

Tissue Specificity

Widely expressed.

Cellular localization

Alternative names

HRAS1, HRAS, GTPase HRas, H-Ras-1, Ha-Ras, Transforming protein p21, c-H-ras, p21ras

swissprot:P01112 omim:164790 omim:190020 omim:190070 swissprot:P01116 entrezGene:3265 entrezGene:4893 entrezGene:3845 swissprot:P01111